Monophosphate 32P-postlabeling assay of DNA adducts from 1,2:3,4-diepoxybutane, the most genotoxic metabolite of 1,3-butadiene: In vitro methodological studies and in vivo dosimetry

Mutation Research - Genetic Toxicology

Volumn 371, Issue 1-2, 1996, Pages 87-104

  Mabon, N ^a   Moorthy, B ^a   Randerath, E ^a   Randerath, K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

1,2:3,4 Diepoxybutane; 1,3 Butadiene; 32P Postlabeling; Adenine adduct; Dinucleotide monophosphate assay; DNA adduct; Dose response; Dosimetry; Mouse skin

Indexed keywords

1,3 BUTADIENE; 1,3 BUTADIENE DERIVATIVE; 1,3-BUTADIENE; BUTADIENE DIEPOXIDE; EPOXIDE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DNA ADDUCT; DNA BINDING; DNA DETERMINATION; DOSE RESPONSE; FEMALE; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; TECHNIQUE; THIN LAYER CHROMATOGRAPHY; TOPICAL DRUG ADMINISTRATION; ANIMAL; CATTLE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; RAT;

ANIMALIA;

ANIMALS; AUTORADIOGRAPHY; BUTADIENES; CATTLE; CHROMATOGRAPHY, THIN LAYER; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; FEMALE; MICE; MICE, INBRED ICR; PHOSPHORUS RADIOISOTOPES; RATS;

EID: 0030569259     PISSN: 01651218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1218(96)90098-1     Document Type: Article

References (65)

1. NTP, National Toxicology Program. 1,3-Butadiene. 7th Annual Report on Carcinogens - Summary. 1994;105-108 U.S. Department of Health and Human Services, Technical Resources Inc. Rockville, MD.
2. 1 mice after 60 weeks of inhalation exposure. Science. 227:1985;548-549.
3. 1 mice at low exposure concentrations. Cancer Res. 50:1990;6592-6599.
4. Owen P.E., Glaister J.R., Gaunt I.F., Pullinger D.H. Inhalation toxicity studies with 1,3-butadiene. III. Two year toxicity/carcinogenicity study in rats. Am. Ind. Hyg. Assoc. J. 48:1987;407-413.
5. Bond J.A., Recio L., Andjelkovich D. Epidemiological and mechanistic data suggest that 1,3-butadiene will not be carcinogenic to humans at exposures likely to be encountered in the environment or workplace. Carcinogenesis. 16:1995;165-171.
6. Melnick R.L., Kohn C.K. Mechanistic data indicate that 1,3-butadiene is a human carcinogen. Carcinogenesis. 16:1995;157-163.
7. Divine B.J., Wendt J.K., Hartman C.M. Cancer mortality among workers at a butadiene production facility. Sorsa M., Peltonen K., Vainio H., Hemminki K. Butadiene and Styrene: Assessment of Health Hazards. 1993;345-362 IARC Scientific Publication No. 127, Lyon.
8. Meinhardt T.J., Lemen R.A., Crandall M.S., Young R.J. Environmental epidemiologic investigation of the styrene-butadiene rubber industry. Scand. J. Work Environ. Health. 8:1982;250-259.
9. Matanosky G.M., Santos-Burgoa C., Schwartz L. Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry (1943-1982). Environ. Health Perspect. 86:1990;107-117.
10. Bolt H.M. Interspecies differences in metabolism and kinetics of 1,3-butadiene, isobutene and styrene. Sorsa M., Peltonen K., Vainio H., Hemminki K. Butadiene and Styrene: Assessment of Health Hazards. 1993;37-44 IARC Scientific Publication No. 127, Lyon.
11. Malvoisin E., Roberfroid M. Hepatic microsomal metabolism of 1,3-butadiene. Xenobiotica. 12:1982;137-144.
12. Csanády G.A., Guengerich F.P., Bond J.A. Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. Carcinogenesis. 13:1992;1143-1153.
13. Duescher R.J., Elfarra A.A. Human liver microsomes are efficient catalysts for 1,3-butadiene oxidation: Evidence for major role by cytochrome P450 2A6 and 2E1. Arch. Biochem. Biophys. 311:1994;342-349.
14. Seaton M.F., Follansbee M.H., Bond J.A. Oxidation of butadiene monoepoxide by cDNA-expressed human cytochrome P450 2E1 and 3A4 and human, mouse and rat liver microsomes. Carcinogenesis. 16:1995;2287-2293.
15. Himmelstein M.W., Turner M.J., Asgharian B., Bond J.A. Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene by inhalation. Carcinogenesis. 15:1994;1479-1486.
16. Himmelstein M.W., Asgharian B., Bond J.A. High concentrations of butadiene epoxides in livers and lungs of mice compared to rats exposed to 1,3-butadiene. Toxicol. Appl. Pharmacol. 132:1995;281-288.
17. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C., Henderson R.E. Disposition of butadiene monoepoxide and butadiene diepoxide in various tissues of rats and mice following a low-level inhalation exposure to 1,3-butadiene. Carcinogenesis. 16:1995;1723-1731.
18. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C. Jr., Pei L., Henderson R.F. Gender differences in the metabolism of 1,3-butadiene in Sprague-Dawley rats following a low-level inhalation exposure. Carcinogenesis. 16:1995;2875-2878.
19. De Meester. Genotoxic properties of 1,3-butadiene. Mutation Res. 195:1988;273-281.
20. Tice R.R., Boucher R., Luke C.A., Shelby M.D. Comparative cytogenetic analysis of bone marrow damage induced in male B6C3F1 mice by multiple exposures to gaseous 1,3-butadiene. Environ. Mutagen. 9:1987;235-250.
21. Cunningham M.J., Choy W.N., Arce G.T., Rickard L.B., Vlachos D.A., Kinney L.A., Sariff A.M. In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. Mutagenesis. 1:1986;449-452.
22. Autio K., Renzi L., Catalan J., Albrecht O.E., Sorsa M. Induction of micronuclei in peripheral blood and bone marrow erythrocytes of rats and mice exposed to 1,3-butadiene by inhalation. Mutation Res. 309:1994;37-44.
23. Cochrane J.E., Skopek T.R. Mutagenicity of butadiene and its metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis. 15:1994;719-723.
24. 1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res. 50:1990;4818-4823.
25. Wiseman R.W., Cochran C., Dietrich W., Lander E.S., Söderkvist P. Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: Frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. 2nd Edn. Proc. Natl. Acad. Sci. USA. 91:1994;3759-3763.
26. IARC Monographs. Diepoxybutane. IARC Monog. Evaluat. Carcinogen. Risk Chem. Man 11 (cadmium, nickel, some epoxides, miscellaneous industrial chemicals and general considerations on volatile anaesthetics). 1976;115-123 International Agency for Resarch on Cancer, Lyon.
27. Sasiadek M., Norppa H., Sorsa M. 1,3-butadiene and its epoxides induce sister-chromatid exchanges in human lymphocytes in vitro. Mutation Res. 261:1991;117-121.
28. Cochrane J.E., Skopek T.T. Mutagenicity of butadiene and its epoxide metabolites: I. Mutagenic potential of 1,2-epoxybutene, 1,2,3,4-diepoxybutane and 3,4-epoxy-1,2-butanediol in cultured human lymphoblasts. Carcinogenesis. 15:1994;713-717.
29. Gervasi P.G., Citti L., Del Monte M., Longo V., Benetti D. Mutagenicity and chemical reactivity of epoxidic intermediates of the isoprene metabolism and other structurally related compounds. Mutation Res. 156:1985;77-82.
30. Millard J.T., White M.M. Diepoxybutane crosslinks DNA at 5′-GNC sequences. Biochemistry. 32:1993;2120-2124.
31. Jelitto B., Vangala B.R., Laib R.J. Specifies differences in DNA damage by butadiene: role of diepoxybutane. Arch. Toxicol., Suppl. 13:1989;246-249.
32. Brookes P., Lawley P.D. The alkylation of guanosine and guanylic acid. J. Chem. Soc. 63:1961;3923-3928.
33. 32P-post-labeling. Carcinogenesis. 15:1994;1903-1910.
34. Citti L., Gervasi P.G., Turchi G., Bellucci G., Bianchini R. The reaction of 3,4-epoxybutene with deoxyguanosine and DNA in vitro: synthesis and characterization of the main adducts. Carcinogenesis. 5:1984;47-52.
35. Osterman-Golkar S., Bond J.A. Biomonitoring of 1,3-butadiene and related compounds. Environ. Health Perspect. 1996;. in press.
36. Sorsa M., Autio K., Demopoulos N.A., Järventaus H., Rössner P., Srám R.J., Stephanou G., Vlachodimitropoulos D. Human cytogenetic biomonitoring of occupational exposure to 1,3-butadiene. Mutation Res. 309:1994;321-326.
37. Ward J.B., Ammenheuser M.M., Bechtold W.E., Whorton E.B. Jr., Legator M.S. hprt mutant lymphocyte frequencies in workers at a 1,3-butadiene production plant. Environ. Health Perspect. 102:1994;79-85.
38. Au W.W., Bechtold W.E., Whorton E.B. Jr., Legator M.S. Chromosome aberrations and response to γ-ray challenge in lymphocytes of workers exposed to 1,3-butadiene. Mutation Res. 334:1995;125-140.
39. Peltonen K., Koivisto P., Neagu I., Kostiainen R., Kilpeläinen I., Sorsa M. Estimating internal dose of 1,3-butadiene: preliminary data on use of modified purine bases as markers of exposure. Sorsa M., Peltonen K., Vainio H., Hemminki K. Butadiene and Styrene: Assessment of Health Hazards. 1993;119-126 IARC Scientific Publications no. 127, Lyon.
40. 32P-labeling test for DNA damage. 2nd Edn. Proc. Natl. Acad. Sci. USA. 78:1981;6126-6129.
41. 32P-postlabeling methods for DNA adduct detection: Overview and critical evaluation. Drug Metabol. Rev. 26:1994;67-85.
42. Hemminki K., Grzybowska E., Chorazy M., Twardowska-Saucha K., Sroczynski J.W., Putman K.L., Randerath K., Phillips D.H., Hewer A. Aromatic DNA adducts in white blood cells of coke workers. Int. Arch. Occup. Environ. Health. 62:1990;467-470.
43. Schoket B. Monitoring occupational exposure to carcinogens. Phillips D.H., Castegnaro M., Bartsch H. Postlabelling Methods for Detection of DNA Adducts. 1993;341-347 IARC Scientific Publication No. 124, Lyon.
44. 32P-postlabeling of DNA adducts formed after exposure to epoxybutene and diepoxybutane. Phillips D.H., Castegnaro M., Bartsch H. Postlabelling Methods for Detection of DNA Adducts. 2nd Edn. IARC Scientific Publication No. 124. 1993;277-282 IARC, Lyon.
45. 32P-postlabeling assay based on the specific enzymatic conversion of bulky DNA lesions to radiolabeled dinucleotides and nucleoside 5′-monophosphates. Carcinogenesis. 7:1989;1231-1239.
46. Randerath K., Randerath E. Ion-exchange thin-layer chromatography. XV. Preparation, properties and applications of paper-like PEI-cellulose sheets. J. Chromatogr. 22:1966;110-117.
47. Gupta R.C. Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. 2nd Edn. Proc. Natl. Acad. Sci. USA. 81:1984;6943-6947.
48. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis. 7:1986;1543-1551.
49. 32P-postlabeled monophosphate 7,12-dimethylbenz[α]anthracene-DNA adducts. Carcinogenesis. 11:1990;159-164.
50. Zar J.H. Simple linear correlation. Zar J.H. Biostatistical Analysis. 2nd Edn. 1984;306-327 Prentice-Hall Inc. Englewood Cliffs, NJ.
51. Randerath K., Gupta K.P., van Golen K.L. Altered fidelity of a nucleic acid modifying enzyme, T4 polynucleotide kinase, by safrole-induced DNA damage. Carcinogenesis. 14:1993;1523-1529.
52. 32P-postlabeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogens and methylating agents. Carcinogenesis. 5:1984;231-243.
53. Randerath K., Randerath E., Smith C.V., Chang J. Structural origins of bulky oxidative DNA adducts (Type II I-compounds) as deduced by oxidation of oligonucleotides of known sequence. Chem. Res. Toxicol. 9:1996;247-254.
54. 32P-postlabeling. Gledhill B.L., Mauro F. New Horizons of Biological Dosimetry. 1991;219-228 Wiley-Liss, New York.
55. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis. 14:1993;2007-2012.
56. Sisk S.C., Pluta L.J., Bond J.A., Recio L. Molecular analysis of lacI mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis. 15:1994;471-477.
57. Reddy M.V., Hemminki K., Randerath K. Postlabeling analysis of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells of foundry workers. J. Toxicol. Environ. Health. 34:1991;177-185.
58. 14C]1,3-butadiene. Toxicol. Lett. 30:1986;131-136.
59. Poirier M.C. Human exposure monitoring, dosimetry, and cancer risk assessment: The use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA. Drug Metabol. Rev. 26:1994;87-109.
60. Dunn B.P. Wide-range linear dose-response curve for DNA binding of orally administered benzo[a]pyrene in mice. Cancer Res. 43:1983;2654-2658.
61. Lutz W.K. Dose-response relationship and low dose extrapolation in chemical carcinogenesis. Carcinogenesis. 11:1990;1243-1247.
62. Gupta K.P., van Golen K.L., Putman K.L., Randerath K. Formation and persistence of safrole adducts over a 10 000 fold dose range in mouse liver. Carcinogenesis. 14:1993;1517-1521.
63. Poirier M.C., Beland F.A. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: Implications for DNA adduct-based human cancer risk assessment. Chem. Res. Toxicol. 5:1992;749-755.
64. Lutz W.K. Quantitative evaluation of DNA-binding data in vivo for low-dose extrapolations. Arch. Toxicol. 11:1987;66-74.
65. 32P-postalbeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis. 15:1994;2087-2094.